Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 5, 2017
Event: Entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics
This filing reports a capital raise event rather than periodic operating results. Specific metrics include:
- Shares Issued: 1,196,291 shares of Common Stock.
- Price Per Share: $3.10.
- Aggregate Purchase Price: Approximately $3.7 million.
- Investor Type: Accredited investors.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a financial statement.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the private placement. The company entered into Subscription Agreements obligating the sale of the shares to investors. Additionally, a Registration Rights Agreement was executed, requiring the company to file a registration statement for the resale of these shares.
Guidance, Outlook, and Risks
Registration Obligations: The company must file a registration statement with the SEC to register the shares for resale. Failure to meet specific registration deadlines may trigger liquidated damages.
Liquidated Damages: If the company fails to meet registration obligations, it must pay investors 1.0% of the aggregate purchase price per month, capped at 10.0%.
Regulatory Status: The shares were sold under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They are not registered and cannot be resold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the final closing date and receipt of the $3.7 million proceeds.
- Monitor the filing status of the Registration Statement required for the resale of the 1,196,291 shares.
- Assess the dilution impact of the new shares on existing shareholders.
- Review the specific deadlines in the Registration Rights Agreement to evaluate the risk of liquidated damages.